Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005646
Status:
COMPLETED
Last Update Posted:
2016-07-14
First Post:
2000-05-02
Brief Title:
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients who have extensive-stage small cell lung cancer
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients who have extensive-stage small cell lung cancer
Detailed Description:
OBJECTIVES I Determine the complete and overall response rate to paclitaxel in patients with previously untreated extensive stage small cell lung cancer II Determine the overall and progression free survival of these patients in response to this treatment regimen III Determine the toxicity of this treatment regimen in this patient population
OUTLINE This is a multicenter study Patients receive paclitaxel IV over 3 hours weekly for 6 consecutive weeks Treatment continues every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 2 months for 1 year then every 3 months for 2 years and then annually for 2 years
OUTLINE This is a multicenter study Patients receive paclitaxel IV over 3 hours weekly for 6 consecutive weeks Treatment continues every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 2 months for 1 year then every 3 months for 2 years and then annually for 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067826 | REGISTRY | NCI Physician Data Query | httpsreporternihgovquickSearchU10CA031946 |
| U10CA031946 | NIH | None | None |
| CLB-39901 | None | None | None |